Black Cohosh for Menopause: Cautious Yes, Cautious No

← Back to articles

Black cohosh (Actaea racemosa; older name Cimicifuga racemosa) is the most commonly used herbal supplement for menopausal symptoms in Western countries. It occupies an awkward place in the evidence landscape: effective enough in some trials to receive attention from menopause societies, but unreliable enough across studies and flagged often enough in case reports that regulators have mandated liver-warning labels.

The hot flash evidence

A Cochrane review of 16 placebo-controlled trials (n=2,027) found no consistent benefit on the frequency or intensity of hot flushes — some trials showed modest improvement, others showed none, and pooling did not produce a robust effect (Leach 2012; PMID 22786509; DOI 10.1002/14651858.CD007244.pub2). The 2023 North American Menopause Society non-hormone therapy position statement does not recommend black cohosh for vasomotor symptoms, citing inconsistent efficacy and safety concerns (NAMS 2023). The German standardised iCR/Remifemin extract has the most consistent individual-trial record but doesn't reliably outperform placebo in pooled analyses.

Not phytoestrogenic

Unlike soy isoflavones or red clover, black cohosh does not bind oestrogen receptors. The mechanism is unclear and likely involves serotonergic and dopaminergic effects. That spares it the theoretical endometrial-stimulation risk of phytoestrogens, but it also means it doesn't reliably address oestrogen-dependent symptoms like vaginal atrophy or bone loss.

The hepatotoxicity question

Since the late 1990s, multiple post-marketing case reports have linked black cohosh products to acute hepatitis, with a small number progressing to transplantation. A structured causality reanalysis of 69 reported cases concluded that confounders (concomitant medication, comorbid liver disease, product mislabelling) made a definitive causal link difficult, with only a minority meeting probable or highly probable causality (Teschke 2009; PMID 19010650). RCT-level data have not shown elevated liver enzyme rates. The EU regulator's position is that idiosyncratic hepatotoxicity is rare but plausible, and labels must warn users to discontinue with any signs of liver injury (fatigue, dark urine, jaundice, pale stools).

Safety and dose

Typical dose is 20–40 mg twice daily of standardised iCR/Remifemin extract or equivalent (40–80 mg total). Evidence is strongest for use up to 6 months. Avoid in pregnancy and breastfeeding (insufficient data), and use with caution in breast-cancer survivors. Avoid combination with other hepatotoxic medications and consider checking liver enzymes at baseline and during use. Stop 2 weeks before elective surgery.

Where it fits

A reasonable option for mild-to-moderate vasomotor symptoms in people who cannot or prefer not to use HRT, SSRIs/SNRIs, or gabapentin, and who don't have liver risk factors. A 6-month review point is sensible: if symptoms aren't materially better, stop.